Alpa Laboratories (BOM:532878) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532878 Alpa Laboratories Ltd BOM:532878
73 GF Score
Price ₹63.03
GF Value ₹93.00
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Alpa Laboratories Cyclically Adjusted Revenue per Share?

Alpa Laboratories BOM:532878 +1.33% 73 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates BOM:532878 with a GF Score™ of 73/100 and a GF Value™ of ₹93.00 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alpa Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹11.960. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Alpa Laboratories's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Alpa Laboratories was 3.50% per year. The lowest was 3.50% per year. And the median was 3.50% per year.

As of today (2026-08-24), Alpa Laboratories's current stock price is ₹63.03. Alpa Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Alpa Laboratories's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alpa Laboratories was 2.62. The lowest was 0.96. And the median was 1.73.


Alpa Laboratories  (BOM:532878) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alpa Laboratories was 2.62. The lowest was 0.96. And the median was 1.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alpa Laboratories Cyclically Adjusted Revenue per Share Related Terms


Alpa Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Alpa Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpa Laboratories Cyclically Adjusted Revenue per Share Chart

Alpa Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 48.39 49.72 51.36 53.68

Alpa Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.15 52.98 53.46 53.68 0.00

BOM:532878 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alpa Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpa Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpa Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alpa Laboratories's Cyclically Adjusted PS Ratio falls into.


BOM:532878
73GF Score
Alpa Laboratories Ltd BOM:532878
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpa Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alpa Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.96/167.3573*167.3573
=11.960

Current CPI (Jun. 2026) = 167.3573.

Alpa Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 9.075 96.780 15.693
201412 6.543 96.780 11.314
201503 6.716 97.163 11.568
201506 3.927 99.841 6.583
201509 5.957 101.753 9.798
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201809 7.173 115.142 10.426
201812 12.340 115.142 17.936
201903 6.538 118.202 9.257
201906 9.648 120.880 13.358
201909 11.175 123.175 15.183
201912 11.504 126.235 15.252
202003 18.836 124.705 25.278
202006 7.760 127.000 10.226
202009 11.559 130.118 14.867
202012 15.739 130.889 20.124
202103 11.298 131.771 14.349
202106 14.933 134.084 18.639
202109 12.492 135.847 15.390
202112 13.937 138.161 16.882
202203 11.113 138.822 13.397
202206 10.699 142.347 12.579
202209 6.705 144.661 7.757
202212 12.965 145.763 14.886
202303 13.767 146.865 15.688
202306 10.191 150.280 11.349
202309 15.388 151.492 17.000
202312 13.142 152.924 14.382
202403 10.743 153.035 11.748
202406 10.183 155.789 10.939
202409 11.875 157.882 12.588
202412 12.426 158.323 13.135
202503 17.851 157.552 18.962
202506 9.078 159.755 9.510
202509 11.670 162.289 12.034
202512 13.738 163.281 14.081
202603 14.921 164.272 15.201
202606 11.960 167.357 11.960

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Alpa Laboratories (BOM:532878) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alpa Laboratories and its competitors.
Is Alpa Laboratories' Cyclically Adjusted Revenue per Share too high?
Alpa Laboratories' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Alpa Laboratories has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alpa Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Alpa Laboratories' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alpa Laboratories and its competitors. Alpa Laboratories's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alpa Laboratories (BOM:532878) is currently considered Possible Value Trap. The stock's GF Value™ is ₹93.00, compared to a current price of ₹63.03 — trading 32.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Alpa Laboratories' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Alpa Laboratories (BOM:532878), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alpa Laboratories (BOM:532878) Overvalued in 2026?

Based on GuruFocus' analysis, Alpa Laboratories stock appears to be undervalued. The current stock price of ₹63.03 is trading 32.2% below its estimated GF Value™ of ₹93.00. GuruFocus considers Alpa Laboratories to be Possible Value Trap.

Key valuation signals for BOM:532878:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹93.00 vs. price of ₹63.03 (32.2% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the BOM:532878 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alpa Laboratories Business Description

Other Exchanges ALPA:India
Address 33/2, A.B. Road, Pigdamber, Rau, Indore, MP, IND, 453446
Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the drug and chemical business segment. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.
73GF Score

Get the complete analysis for BOM:532878

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹63.03
Price
₹93.00
GF Value